Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.

Abstract

The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas. The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl-6) and activated B-cell immunophenotype markers (FoxP1, Mum1). During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B-cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival. Advanced International Prognostic Index (IPI) score and combined-modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B-cell lymphoma as elsewhere.